bioRxiv (Cold Spring Harbor Laboratory)
July 7, 2025
Akila Ram, Austen B Casey, Robert C. Malenka et al.
2 citations
preprint
Abstract The psychedelic psilocybin may have lasting therapeutic effects for patients with chronic pain syndromes. Some clinical and preclinical data suggest these putative benefits derive from direct analgesic effects. However, this possibility has not been comprehensively tested in preclinical models. Here, we show that psilocybin is not analgesic over a range of doses across multiple pain...
Arts, Culture and Language
July 6, 2025
Yutong Song
Psilocybin, also known as “magic mushrooms,” is naturally found in psychedelic compound from different types of mushrooms. The utility of psilocybin for spiritual and therapeutic purposes has already go through several centuries. Scientific research on these compounds gained traction in the mid-20th century, the increasing interest in the possible therapeutic benefits of psilocybin has led to...
Pharmaceuticals
July 6, 2025
Pauline Braekow, Joachim Neumann, Uwe Kirchhefer et al.
Background/Objectives: Hallucinogenic substances such as psilocybin, psilocin, ergometrine, ergotamine, and lysergic acid diethylamide (LSD) have been demonstrated to enhance the force of contraction (FOC), in part due to the phosphorylation of phospholamban in human atrial preparations via 5-HT4 serotonin receptors and/or H2 histamine receptors. However, whether psilocybin or psilocin acts at...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
July 5, 2025
Hynek Danda, Kristýna Mazochová, Klára Šíchová et al.
1 citation
Baeocystin is a naturally occurring tryptamine-based compound found in various psychoactive mushrooms, including in several species of Psilocybe genus. Due to its structural similarity to psilocybin, which has shown a therapeutic potential in treatment of psychiatric disorders, there is a growing interest in investigating whether baeocystin exhibits comparable effects. This study investigated...
ACS Central Science
July 3, 2025
Mara Johnson-Groh
3 citations
Some scientists think that including secondary compounds from psychedelic mushrooms can make for better drugs. With scarce data, others remain skeptical.
Journal of Labelled Compounds and Radiopharmaceuticals
July 1, 2025
Rodney D. Brown, Niall M. Hamilton, Connor Mallon et al.
1 citation
ABSTRACT Three novel 14 C‐labelled isotopologues of the psychoactive agents psilocin, psilocybin and 5‐methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT) were synthesised, all labelled at the 2‐position of the indole. The syntheses involved incorporating the 3‐dimethylaminoethyl substituent common to all three substances onto a 4‐ or 5‐substituted indole intermediate via successive treatments with...
Swiss Medical Weekly
July 1, 2025
Samuel E Christen, Elias Bekka, Yasmin Schmid et al.
3 citations
Psychoactive substances are compounds that can influence perception, consciousness, cognition, and emotions. The psychoactive substances caffeine, nicotine, cannabis, and psilocybin all originate from natural sources and can be used without complex processing or synthesis. Their natural availability has contributed to a long-standing history of human use and cultural significance. Caffeine and...
Psychoactives
July 1, 2025
David W. Lawrence, Alex P. Di Battista, Michael G. Hutchison
1 citation
Background: Persisting symptoms after concussion is a complex syndrome warranting exploration into further treatment options. Emerging research highlights the potential of classic psychedelics, such as psilocybin, in managing neuropsychiatric conditions and promoting neuroprotection. Case Report: A case is presented of a 22-year-old male intercollegiate athlete who sustained a concussion and...
Molecular Psychiatry
July 1, 2025
Rebecca Harding, Neomi Singer, Matthew B. Wall et al.
correction
The following part of the abstract had a minor error: ‘Following PT, there was greater activation in the ventromedial prefrontal cortex and sensory regions, and reduced activation in the angular gyrus.’ This is now corrected to ‘Following PT, there was decreased activation in the ventromedial prefrontal cortex and angular gyrus, and greater activation in sensory regions.’ The original article...
Archiv der Pharmazie
July 1, 2025
Judith Stirn, Christian D. Klein
Acyloxymethyl (ACOM) derivatives of tryptamines such as the psychedelic drug psilocin and the anti-migraine drug sumatriptan bear potential as prodrugs. Previous synthetic approaches suffer from insufficient chemoselectivity between the desired functionalization of the phenolic (psilocin) or sulfonamide (sumatriptan) groups versus other reactive groups in the parent drugs. We report a novel...